To further delineate the impact of CLDN8 on drug sensitivity, we compared the IC50 values between CLDN8 wild-type (WT) and CLDN8 knockdown (KD) breast cancer cell lines for a panel of therapies (Table 2). The gene discussed is CLDN8; the disease is breast carcinoma.